Cat. No.: HY-17015A

Peramivir

(Synonyms: RWJ-270201; BCX-1812)

13 Cited Publications

고객리뷰

Based on 13 publication(s) in Google Scholar

Peramivir is an novel cyclopentane neuraminidase inhibitor of influenza virus. Peramivir has antiviral activity and anti-cytokines stom effects. Peramivir can be used for the research of COVID-19.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Purity: 99.94%
CAS No.: 330600-85-6
화학식: C₁₅H₂₈N₄O₄
분자량:328.41

보관:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Peramivir Chemical Structure

CAS No.: 330600-85-6

사이즈

가격

재고

수량

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- 제품 설명
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (13)
용액&용해도
- In Vitro
순도&문서
References
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

IC₅₀ & Target

IKK-α

STAT3

ERK1

ERK2

All IKK Isoforms :

All JNK Isoforms :

All STAT Isoforms :

All p38 MAPK Isoforms :

All ERK Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
HEK293	IC₅₀	0.07 nM Compound: 5	Inhibition of oseltamivir-resistant Influenza A virus A/WSN/1933(H1N1) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate ad Inhibition of oseltamivir-resistant Influenza A virus A/WSN/1933(H1N1) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate ad	[PMID: 27167096]
HEK293	IC₅₀	0.3 nM Compound: 5	Inhibition of oseltamivir-resistant Influenza A virus A/Vietnam/1194/2004(H5N1) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by sub Inhibition of oseltamivir-resistant Influenza A virus A/Vietnam/1194/2004(H5N1) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by sub	[PMID: 27167096]
HEK293	IC₅₀	0.7 nM Compound: 5	Inhibition of Influenza A virus A/Brisbane/10/2007(H3N2) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measure Inhibition of Influenza A virus A/Brisbane/10/2007(H3N2) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measure	[PMID: 27167096]
HEK293	IC₅₀	0.8 nM Compound: 5	Inhibition of Influenza A virus A/Shanghai/01/2014(H7N9) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measure Inhibition of Influenza A virus A/Shanghai/01/2014(H7N9) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measure	[PMID: 27167096]
HEK293	IC₅₀	146 nM Compound: 5	Inhibition of Influenza A virus A/Brisbane/10/2007(H3N2) recombinant neuraminidase R292K mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition meas Inhibition of Influenza A virus A/Brisbane/10/2007(H3N2) recombinant neuraminidase R292K mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition meas	[PMID: 27167096]
HEK293	IC₅₀	225 nM Compound: 5	Inhibition of Influenza A virus A/Brisbane/10/2007(H3N2) recombinant neuraminidase E119A mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition meas Inhibition of Influenza A virus A/Brisbane/10/2007(H3N2) recombinant neuraminidase E119A mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition meas	[PMID: 27167096]
HEK293	IC₅₀	3.3 nM Compound: 5	Inhibition of oseltamivir-resistant Influenza A virus A/Vietnam/1194/2004(H5N1) recombinant neuraminidase H275Y mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by Inhibition of oseltamivir-resistant Influenza A virus A/Vietnam/1194/2004(H5N1) recombinant neuraminidase H275Y mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by	[PMID: 27167096]
HEK293	IC₅₀	3.6 nM Compound: 5	Inhibition of Influenza A virus A/WSN/1933(H1N1) recombinant neuraminidase H275Y mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measured aft Inhibition of Influenza A virus A/WSN/1933(H1N1) recombinant neuraminidase H275Y mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measured aft	[PMID: 27167096]
MDCK	IC₅₀	0.2 nM Compound: Peramivir	Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222M mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Cal Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222M mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Cal	[PMID: 19651908]
MDCK	IC₅₀	0.2 nM Compound: Peramivir	Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Caledo Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Caledo	[PMID: 19651908]
MDCK	IC₅₀	0.3 nM Compound: Peramivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222M mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222M mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose	[PMID: 19651908]
MDCK	IC₅₀	0.3 nM Compound: Peramivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222V mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222V mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose	[PMID: 19651908]
MDCK	IC₅₀	0.3 nM Compound: Peramivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose	[PMID: 19651908]
MDCK	IC₅₀	0.3 nM Compound: Peramivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam/12 Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam/12	[PMID: 19651908]
MDCK	IC₅₀	0.3 nM Compound: Peramivir	Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222V mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Cal Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222V mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Cal	[PMID: 19651908]
MDCK	IC₅₀	1 nM Compound: Peramivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase D198G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase D198G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam	[PMID: 19651908]
MDCK	IC₅₀	142.4 nM Compound: Peramivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose	[PMID: 19651908]
MDCK	IC₅₀	213 nM Compound: Peramivir	Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222V and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222V and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus	[PMID: 19651908]
MDCK	IC₅₀	27 nM Compound: Peramivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam	[PMID: 19651908]
MDCK	IC₅₀	3 nM Compound: Peramivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam	[PMID: 19651908]
MDCK	IC₅₀	43.6 nM Compound: Peramivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose	[PMID: 19651908]
MDCK	IC₅₀	562.1 nM Compound: Peramivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222V and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222V and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose	[PMID: 19651908]
MDCK	IC₅₀	82.8 nM Compound: Peramivir	Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Cal Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Cal	[PMID: 19651908]
MDCK	IC₅₀	891.4 nM Compound: Peramivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222M and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222M and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose	[PMID: 19651908]
MDCK	IC₅₀	95.5 nM Compound: Peramivir	Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222M and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222M and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus	[PMID: 19651908]
MDCK	IC₅₀	0.28 nM Compound: peramivir	Antiviral activity against Influenza A virus (A/Washington/01/2007 (H3N2)) measured in MDCK cells by NA inhibition assay Antiviral activity against Influenza A virus (A/Washington/01/2007 (H3N2)) measured in MDCK cells by NA inhibition assay	[PMID: 20194700]
MDCK	IC₅₀	0.43 nM Compound: peramivir	Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 1 with neuraminidase E119V mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by NA inhibition assay Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 1 with neuraminidase E119V mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by NA inhibition assay	[PMID: 20194700]
MDCK	IC₅₀	0.5 nM Compound: peramivir	Antiviral activity against Influenza A virus (A/Washington/01/2007 (H3N2)) measured in MDCK cells by fluorescent NA inhibition assay Antiviral activity against Influenza A virus (A/Washington/01/2007 (H3N2)) measured in MDCK cells by fluorescent NA inhibition assay	[PMID: 20194700]
MDCK	IC₅₀	0.51 nM Compound: peramivir	Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) with neuraminidase E119(V/I) mutant isolated from immunocompromized patient measured after X/CD3 additional passages in MDCK cells by NA inhibition assay Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) with neuraminidase E119(V/I) mutant isolated from immunocompromized patient measured after X/CD3 additional passages in MDCK cells by NA inhibition assay	[PMID: 20194700]
MDCK	IC₅₀	0.9 nM Compound: peramivir	Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 2 with neuraminidase E119I mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by NA inhibition assay Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 2 with neuraminidase E119I mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by NA inhibition assay	[PMID: 20194700]
MDCK	IC₅₀	1.47 nM Compound: peramivir	Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 1 with neuraminidase E119V mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by fluorescent NA inhibition assay Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 1 with neuraminidase E119V mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by fluorescent NA inhibition assay	[PMID: 20194700]
MDCK	IC₅₀	214.07 nM Compound: peramivir	Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 2 with neuraminidase E119I mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by fluorescent NA inhibition assay Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 2 with neuraminidase E119I mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by fluorescent NA inhibition assay	[PMID: 20194700]
MDCK	IC₅₀	33.56 nM Compound: peramivir	Antiviral activity against sInfluenza A virus (A/Texas/12/2007 (H3N2)) with neuraminidase E119(V/I) mutant isolated from immunocompromized patient measured after X/CD3 additional passages in MDCK cells by fluorescent NA inhibition assay Antiviral activity against sInfluenza A virus (A/Texas/12/2007 (H3N2)) with neuraminidase E119(V/I) mutant isolated from immunocompromized patient measured after X/CD3 additional passages in MDCK cells by fluorescent NA inhibition assay	[PMID: 20194700]
MDCK	IC₅₀	1.72 nM Compound: Peramivir	Antiviral activity against influenza A virus infected in MDCK cells assessed as inhibition of neuraminidase activity by fluorimetric assay Antiviral activity against influenza A virus infected in MDCK cells assessed as inhibition of neuraminidase activity by fluorimetric assay	[PMID: 20713668]
MDCK	IC₅₀	3 nM Compound: Peramivir	Antiviral activity against influenza B virus infected in MDCK cells assessed as inhibition of neuraminidase activity by fluorimetric assay Antiviral activity against influenza B virus infected in MDCK cells assessed as inhibition of neuraminidase activity by fluorimetric assay	[PMID: 20713668]
MDCK	IC₅₀	3.51 nM Compound: Peramivir	Antiviral activity against influenza A virus H3N2 infected in MDCK cells assessed as inhibition of neuraminidase activity by fluorimetric assay Antiviral activity against influenza A virus H3N2 infected in MDCK cells assessed as inhibition of neuraminidase activity by fluorimetric assay	[PMID: 20713668]
MDCK	IC₅₀	9.43 nM Compound: Peramivir	Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as inhibition of neuraminidase activity by fluorimetric assay Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as inhibition of neuraminidase activity by fluorimetric assay	[PMID: 20713668]
MDCK	EC₅₀	1.5 nM Compound: 5	Antiviral activity against oseltamivir-resistant Influenza A virus A/WSN/1933(H1N1) infected in MDCK cells assessed as protection against virus-induced cytopathic effect after 48 hrs by CellTiter 96 AQueous Non-Radioactive cell proliferation assay Antiviral activity against oseltamivir-resistant Influenza A virus A/WSN/1933(H1N1) infected in MDCK cells assessed as protection against virus-induced cytopathic effect after 48 hrs by CellTiter 96 AQueous Non-Radioactive cell proliferation assay	[PMID: 27167096]
MDCK	CC₅₀	>1 x 10⁵ nM Compound: 5	Cytotoxicity against MDCK cells after 48 hrs by CellTiter 96 AQueous Non-Radioactive cell proliferation assay Cytotoxicity against MDCK cells after 48 hrs by CellTiter 96 AQueous Non-Radioactive cell proliferation assay	[PMID: 27167096]
MDCK	CC₅₀	373 μM Compound: 3	Cytotoxicity against MDCK cells infected with Influenza A virus (A/WSN/33(H1N1)) after 72 hrs by CellTiter-Glo assay Cytotoxicity against MDCK cells infected with Influenza A virus (A/WSN/33(H1N1)) after 72 hrs by CellTiter-Glo assay	[PMID: 29141777]
MDCK	CC₅₀	>1 x 10⁵ nM Compound: 4; PE	Cytotoxicity against MDCK cells after 48 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay Cytotoxicity against MDCK cells after 48 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay	[PMID: 29324342]
MDCK	CC₅₀	>200 μM Compound: Peramivir	Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31954881]
MDCK	CC₅₀	>100 μM Compound: Peramivir	Cytotoxicity against MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 34700269]
MDCK	CC₅₀	>101 μM Compound: Peramivir	Cytotoxicity against MDCK cells incubated for 48 hrs by MTT assay Cytotoxicity against MDCK cells incubated for 48 hrs by MTT assay	[PMID: 36521178]

In Vitro

Peramivir (0.3125-40 μM, 4 h) has nontoxicity to macrophage^[1].
Peramivir (2-10 μM, 6-12 h) inhibits cytokine release in LPS-induced hPBMCs^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:

RAW 264.7
Concentration:

0.3125 μM, 0.625 μM, 1.25 μM, 2.5 μM, 5 μM, 10 μM, 20 μM, 40 μM
Incubation Time:

4 h
Result:

Showed no apparent toxicity in the peramivir-treated macrophages at concentrations up to 40 μM.

In Vivo

Peramivir (20-60 mg/kg, Intraperitoneal injection, single dose) inhibits LPS-induced cytokine storm, attenuates acute lung injury and prolongs the survival in cytokine storm syndrome model mice^[1].
Peramivir (75 mg/kg, Intramuscular injection, once a day for 7 days) rescued BALB scid mice from lethal challenge with BR/08 in immunocompromised murine models of infuenza B virus infection^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Cytokine storm syndrome model mice ^[1]
Dosage:

20 mg/kg, 60 mg/kg
Administration:

Intraperitoneal injection (i.p.)
Result:

Decreased 8 cytokines including TNF-a, IFN-a, IFN-γ, chemokines (MCP-1), GM-CSF, IL-1β, IL-6 and IL-12.
Showed less inflammatory cell infiltrations, mild alveolar thickening and less bleeding points or congestion.
Showed significant protective effects to the lung tissues.

Animal Model:

Immunocompromised murine models of infuenza B virus infection^[2]
Dosage:

75 mg/kg
Administration:

Intramuscular injection (i.m.)
Result:

Conferred complete protection against lethality, whether it was administered in one (1×), two (2×), or four (4×) doses, with maximum mean weight loss of 10% to 14%.
Resulted in a trend of decreasing virus replication in the nasal cavities and lungs.
Reduced the virus titers and replication.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 330600-85-6
Appearance Solid
분자량 328.41
화학식 C₁₅H₂₈N₄O₄
Color White to off-white
SMILES

O[C@H]1[C@]([C@H](C(CC)CC)NC(C)=O)([H])[C@H](NC(N)=N)C[C@@H]1C(O)=O
Synonyms

RWJ-270201; BCX-1812
선적

Room temperature in continental US; may vary elsewhere.

보관

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (13)

All

Sort by:

Journal Impact Factor

Nat Commun

Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility. [Abstract]

2013;4:2854. PMID: 24326875
NPJ Digit Med

Predictive modeling & mechanistic validation of synergistic pimodivir combinations for anti-influenza therapy via PB2cap affinity boost. [Abstract]

2025 Nov 21;8(1):712. PMID: 41272280
Emerg Microbes Infect

Efficient airborne transmission of influenza D virus in ferret models and serological evidence of human exposure in Northeast China. [Abstract]

2025 Dec;14(1):2564308. PMID: 41069204
Int Immunopharmacol

Lidocaine inhibits influenza a virus replication by up-regulating IFNα4 via TBK1-IRF7 and JNK-AP1 signaling pathways. [Abstract]

2023 Feb:115:109706. PMID: 36638664
PLoS Pathog

The HN protein of Newcastle disease virus induces cell apoptosis through the induction of lysosomal membrane permeabilization. [Abstract]

2024 Feb 14;20(2):e1011981. PMID: 38354122
Sci Rep

Substitution of I222L-E119V in neuraminidase from highly pathogenic avian influenza H7N9 virus exhibited synergistic resistance effect to oseltamivir in mice. [Abstract]

2021 Aug 11;11(1):16293. PMID: 34381119
Int J Infect Dis

Antiviral susceptibility of SARS-CoV-2 and influenza viruses from 3 co-infected pediatric patients. [Abstract]

2024 Jun 27:107134. PMID: 38944411
Antimicrob Agents Chemother

Development of Novel Anti-influenza Thiazolides with Relatively Broad-Spectrum Antiviral Potentials. [Abstract]

2020 Jun 23;64(7):e00222-20. PMID: 32312780
PLoS One

An easy, rapid, and sensitive method for detection of drug-resistant influenza virus by using a sialidase fluorescent imaging probe, BTP3-Neu5Ac. [Abstract]

2018 Jul 12;13(7):e0200761. PMID: 30001430
PLoS One

Detection of peramivir and laninamivir, new anti-influenza drugs, in sewage effluent and river waters in Japan. [Abstract]

2015 Jun 25;10(6):e0131412. PMID: 26110817
bioRxiv

Inhibiting Glycan Degradation Prevents HIV-Induced Inflammaging and Cognitive Impairment. [Abstract]

2025 Nov 17:2025.11.17.688839. PMID: 41332691
University of Glasgow

2023.
Chemosphere

Fate of new three anti-influenza drugs and one prodrug in the water environment. [Abstract]

2017 Feb:169:550-557. PMID: 27898328

용액&용해도

In Vitro:

1 M HCl : ≥ 100 mg/mL (304.50 mM)

DMSO : < 1 mg/mL (insoluble or slightly soluble)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.0450 mL

15.2249 mL

30.4497 mL

5 mM

0.6090 mL

3.0450 mL

6.0899 mL

10 mM

0.3045 mL

1.5225 mL

3.0450 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

순도&문서

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (286 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Zhang C, et al. Peramivir, an anti-influenza virus drug, exhibits potential anti-cytokine storm effects [J]. Frontiers in Immunology, 2022, 13: 856327. [Content Brief]

[2]. Pascua P N Q, et al. Pathogenicity and peramivir efficacy in immunocompromised murine models of influenza B virus infection [J]. Scientific reports, 2017, 7(1): 7345. [Content Brief]

[3]. Alame M M, et al.. Peramivir: a novel intravenous neuraminidase inhibitor for treatment of acute influenza infections [J]. Frontiers in microbiology, 2016, 7: 450. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
1 M HCl	1 mM	3.0450 mL	15.2249 mL	30.4497 mL	76.1244 mL
	5 mM	0.6090 mL	3.0450 mL	6.0899 mL	15.2249 mL
	10 mM	0.3045 mL	1.5225 mL	3.0450 mL	7.6124 mL
	15 mM	0.2030 mL	1.0150 mL	2.0300 mL	5.0750 mL
	20 mM	0.1522 mL	0.7612 mL	1.5225 mL	3.8062 mL
	25 mM	0.1218 mL	0.6090 mL	1.2180 mL	3.0450 mL
	30 mM	0.1015 mL	0.5075 mL	1.0150 mL	2.5375 mL
	40 mM	0.0761 mL	0.3806 mL	0.7612 mL	1.9031 mL
	50 mM	0.0609 mL	0.3045 mL	0.6090 mL	1.5225 mL
	60 mM	0.0507 mL	0.2537 mL	0.5075 mL	1.2687 mL
	80 mM	0.0381 mL	0.1903 mL	0.3806 mL	0.9516 mL
	100 mM	0.0304 mL	0.1522 mL	0.3045 mL	0.7612 mL

Peramivir

13 Cited Publications

100 mg 견적 받기

Subscribe to the

MedChemExpress

Newsletter

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

상품명:
CAS No.:
Species:
Purity:
수량:

Peramivir

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

Publications Citing Use of MedChemExpress (MCE) Peramivir

All IKK Isoforms

All JNK Isoforms

All STAT Isoforms

All p38 MAPK Isoforms

All ERK Isoforms

Biological Activity

Chemical Information

Publications (13)

용액&용해도

순도&문서

References

Help & FAQs

Complete Stock Solution Preparation Table

Peramivir

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

Publications Citing Use of MedChemExpress (MCE) Peramivir

All IKK Isoforms

All JNK Isoforms

All STAT Isoforms

All p38 MAPK Isoforms

All ERK Isoforms

Biological Activity

Chemical Information

Publications (13)

용액&용해도

순도&문서

References

Help & FAQs

Complete Stock Solution Preparation Table

Peramivir Related Classifications

HY-17015A Related Classifications